Colorectal panel provides detailed cancer information
Answers from the Lab
New information about colorectal cancer has led to updated recommendations for testing and treatment. In this test specific episode of the "Answers From the Lab" podcast, Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' expanded colon panel, which provides enhanced information about prognosis, treatment options and a hereditary cancer syndrome.
"This new expanded panel allows us to address patient needs. It covers a larger number of genes and provides a greater amount of clinically actionable information," Dr. Graham says.
In addition to covering multiple gene mutations, the assay assesses for microsatellite instability and Lynch syndrome. Microsatellite instability is a biomarker for response to checkpoint inhibitor treatment. The American Society of Clinical Oncologists recommends that testing for Lynch syndrome — an inherited cancer syndrome — be performed for all people diagnosed with colorectal cancer.
The MayoComplete Colorectal Cancer Panel uses next generation sequencing and is suitable both for patients with cancer confined to the colon and for cases of metastatic colorectal cancer.
"Being able to address all these patient needs and gain so much useful information in a single assay will be very helpful," Dr. Graham says.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
This assay requires at least 20% tumor nuclei
For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing. In this document, the sizes are given as 4mm x 4mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3mm x 1mm x 10 slides: approximate/equivalent to 36mm(2).
Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block
Additional Information: Unused unstained slides will not be returned
Analytic time: 12 days
Days performed: Monday through Friday
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.